TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9342768

Group type: EXPERIMENTAL
Intervention: 900 mg hypericum extract (LI 160)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1800 mg hypericum extract (LI 160)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 3600 mg hypericum extract (LI 160)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 600 mg hypericum extract t.i.d. (5.6 mg total hypericin daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8396394

Group type: EXPERIMENTAL
Intervention: 4‐MV photons
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 10‐MV photons
Number of subjects: 126

Group type: COMPARATOR
Intervention: 4‐MV or 10‐MV photons
Number of subjects: 126
Study: 3731706

Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque)
Number of subjects: 57

Group type: COMPARATOR
Intervention: sodium/meglumine diatrizoate (Urografin)
Number of subjects: 57
Study: 31713267

Group type: EXPERIMENTAL
Intervention: OPA-15406 0.3%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: OPA-15406 1%
Number of subjects: 73

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: OPA-15406 0.3% and 1%
Number of subjects: 73
Study: 30753178

Group type: EXPERIMENTAL
Intervention: Anterior decompression
Number of subjects: 80

Group type: COMPARATOR
Intervention: Posterior decompression
Number of subjects: 80
Study: 28230596

Group type: EXPERIMENTAL
Intervention: Immediate implant placement with lyophilized bovine bone granules and pericardium membrane covering
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (empty extraction socket left untreated)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between Group I and II
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group II (immediate implants)
Number of subjects: 20
Study: 26298689

Group type: EXPERIMENTAL
Intervention: Animal Fun program
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 511
Study: 23452466

Group type: EXPERIMENTAL
Intervention: High-protein diet from meat (14 en%)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High-protein diet from grain (14 en%)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High-protein diet from dairy (14 en%)
Number of subjects: 47
Study: 21845472

Group type: EXPERIMENTAL
Intervention: Naftopidil 10 mg once daily
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (watchful waiting)
Number of subjects: 131
Study: 18482350

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren 3 x 50 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Occlusal splint therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both treatments (Diclofenac and Occlusal splint therapy)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 29

Group type: COMPARATOR
Intervention: Contralateral, symptom-free TMJ
Number of subjects: 29
Study: 16847036

Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study: 12766922

Group type: EXPERIMENTAL
Intervention: Qigong (The Eight Section Brocades) for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional remedial rehabilitation activities
Number of subjects: 50
Study: 10834776

Group type: EXPERIMENTAL
Intervention: 5 mg of isobaric bupivacaine with 25 microg fentanyl
Number of subjects: 32

Group type: COMPARATOR
Intervention: 10 mg of isobaric (plain) bupivacaine 0.5%
Number of subjects: 32
Study: 9489085

Group type: EXPERIMENTAL
Intervention: Doxazosin (0.5 or 1 mg once daily, up to 12 mg once daily)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 8161441

Group type: EXPERIMENTAL
Intervention: Antiviral treatment (exact dosage and duration not specified)
Number of subjects: 4
Study: 3526984

Group type: EXPERIMENTAL
Intervention: Esmolol (infusion rates between 100 and 300 micrograms X kg‐1 X min‐1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Esmolol (200 micrograms X kg‐1 X min‐1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30770767

Group type: EXPERIMENTAL
Intervention: 12-week yoga program (n=22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standardized educational film program (n=22)
Number of subjects: 44
Study: 30070386

Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy (median: 45 sessions)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Inpatient treatment (average duration: 9 weeks)
Number of subjects: 64
Study: 29104805

Group type: EXPERIMENTAL
Intervention: Frequent self-weighing
Number of subjects: 36
Study: 25648589

Group type: EXPERIMENTAL
Intervention: Guided self-help Internet intervention 'mastery over dementia' (MoD)
Number of subjects: 149
Study: 24121610

Group type: EXPERIMENTAL
Intervention: Subgluteal space technique (30 mL admixture of 1:2 lidocaine 2% and bupivacaine 0.5% with 1:200,000 epinephrine)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Infragluteal technique (30 mL admixture of 1:2 lidocaine 2% and bupivacaine 0.5% with 1:200,000 epinephrine)
Number of subjects: 27
Study: 20858088

Group type: EXPERIMENTAL
Intervention: Radio frequency regional hyperthermia combined with gemcitabine and cisplatin (GP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin (GP) alone
Number of subjects: 80
Study: 17951021

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (SC) as an adjunct to substance abuse treatment-as-usual (TAU)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (SC)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Substance abuse treatment-as-usual (TAU)
Number of subjects: 225
Study: 16971616

Group type: EXPERIMENTAL
Intervention: Matrix detachable coils
Number of subjects: 236
Study: 14983955

Group type: EXPERIMENTAL
Intervention: Serum prostate-specific antigen (PSA) determination, digital rectal examination (DRE), transrectal ultrasonography (TRUS) as screening tests
Number of subjects: 42376

Group type: EXPERIMENTAL
Intervention: Serum PSA level > or = 3.0 ng/mL as an indication for sextant biopsy
Number of subjects: 42376
Study: 10737317

Group type: EXPERIMENTAL
Intervention: Primary unilateral pharyngeal myotomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neurectomy of the pharyngeal plexus in addition to pharyngeal myotomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: No additional surgical procedure
Number of subjects: 60
Study: 7986334

Group type: EXPERIMENTAL
Intervention: Live VZV vaccine (4,000 PFU of Oka strain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated VZV vaccine (similar amount to live vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) immunization (3 months before VZV vaccine)
Number of subjects: 0
Study: 3151688

Group type: EXPERIMENTAL
Intervention: Clindamycin 3x80 mg and Gentamycin 3x80 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Metronidazol 3x500 mg and Gentamycin 3x80 mg
Number of subjects: 54
Study: 30466348

Group type: EXPERIMENTAL
Intervention: Theater-based intervention including a play, value exercises, chlamydia games, condom school, and interactive replay with professional actors and staff from a youth guidance center.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard sex education from school staff (Control group).
Number of subjects: 0
Study: 31204204

Group type: EXPERIMENTAL
Intervention: Exergame rehabilitation using Motion Rehab AVE 3D
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 31
Study: 28196533

Group type: EXPERIMENTAL
Intervention: Iron-fortified cereal (Cer)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Iron-fortified cereal with fruit (Cer + Fr)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Meat (M)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All groups (Cer, Cer + Fr, M)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Meat (M) or Iron-fortified cereal with fruit (Cer + Fr)
Number of subjects: 87
Study: 25211695

Group type: EXPERIMENTAL
Intervention: Order of administration with memory descriptions before well-being scales
Number of subjects: 0

Group type: COMPARATOR
Intervention: Order of administration with well-being scales before memory descriptions
Number of subjects: 0
Study: 23594227

Group type: EXPERIMENTAL
Intervention: MK-0916 (6 mg once daily for 14 days)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MK-0916 (0.4-100 mg single doses)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MK-0916 (0.2-225 mg followed by daily doses of 0.2-100 mg for 13 days)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MK-0916
Number of subjects: 96
Study: 21357934

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous peritoneal dialysis (CPD)
Number of subjects: 50
Study: 19597267

Group type: EXPERIMENTAL
Intervention: Task-oriented strength training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 10
Study: 17785709

Group type: EXPERIMENTAL
Intervention: 12-week yoga intervention (n = 84)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 12-week waitlist control group (n = 44)
Number of subjects: 128
Study: 15131466

Group type: EXPERIMENTAL
Intervention: MCV-4 at 1 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MCV-4 at 4 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MCV-4 at 10 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Licensed meningococcal polysaccharide vaccine (A, C, Y, W-135) at 15 to 18 months
Number of subjects: 90
Study: 11237270

Group type: EXPERIMENTAL
Intervention: Etidronate (2-week administration)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no etidronate)
Number of subjects: 81
Study: 9514486

Group type: EXPERIMENTAL
Intervention: Strabismus at 3 months
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Strabismus at 12 months
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Total prevalence of strabismus in the first year of life
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Retinopathy of prematurity
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Presence of strabismus at 3 months
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Anisometropia, abnormal fixation, and unfavorable retinal structure
Number of subjects: 3030
Study: 7802303

Group type: COMPARATOR
Intervention: General Anesthesia (GA: atropine, halothane, and nitrous oxide)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA: hyperbaric tetracaine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 2277738

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (0.5 mg b.i.d.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 37861

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 142

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Flunitrazepam and Diazepam
Number of subjects: 142
Study: 30372576

Group type: EXPERIMENTAL
Intervention: Cylindrical attachment (LA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ball attachment (RA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crossover phase (both systems)
Number of subjects: 0
Study: 27815605

Group type: EXPERIMENTAL
Intervention: Peptide serum markers
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Two peptides (from apolipoprotein M and apolipoprotein C-IV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor activator, complement factor H, ceruloplasmin, and age
Number of subjects: 45
Study: 25771023

Group type: EXPERIMENTAL
Intervention: Bi‐directional text messaging
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: EMR + reminders
Number of subjects: 121

Group type: COMPARATOR
Intervention: EMR‐only
Number of subjects: 121
Study: 23432146

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 or 40 mg once daily for 4 weeks
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Current therapy (control)
Number of subjects: 1388
Study: 21310833

Group type: EXPERIMENTAL
Intervention: 2 g Acetyl-L-carnitine (ALC) twice a day for 90 days
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo twice a day for 90 days
Number of subjects: 121
Study: 19049504

Group type: EXPERIMENTAL
Intervention: Addenbrooke's Cognitive Examination (ACE)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Scales for Outcomes of Parkinson's disease‐Cognition (SCOPA‐COG)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mini‐mental state examination (MMSE)
Number of subjects: 44
Study: 16696839

Group type: EXPERIMENTAL
Intervention: Dichotic listening test under forced right attention condition
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dichotic listening test under forced left attention condition
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dichotic listening test under non‐forced attention condition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dichotic listening test
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: General cognitive functioning
Number of subjects: 50
Study: 15351417

Group type: EXPERIMENTAL
Intervention: Post-operative closed-suction drain (Group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No post-operative closed-suction drain (Group A)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 78
Study: 11323328

Group type: EXPERIMENTAL
Intervention: remifentanil/isoflurane/propofol
Number of subjects: 304

Group type: COMPARATOR
Intervention: fentanyl/isoflurane/propofol
Number of subjects: 304
Study: 9153367

Group type: EXPERIMENTAL
Intervention: p55‐IgG, 0.083 mg/kg
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: p55‐IgG, 0.042 mg/kg
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: p55‐IgG (both doses)
Number of subjects: 498
Study: 8162628

Group type: EXPERIMENTAL
Intervention: 30 mg isosorbide dinitrate (ISDN) treatment for 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glyceryl trinitrate (GTN) before ISDN treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glyceryl trinitrate (GTN) after ISDN treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks
Number of subjects: 14
Study: 3074604

Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 0
Study: 31853557

Group type: EXPERIMENTAL
Intervention: 5 μg LSD
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 μg LSD
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 20 μg LSD
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29502856

Group type: EXPERIMENTAL
Intervention: Palpable tumors
Number of subjects: 1576

Group type: COMPARATOR
Intervention: Nonpalpable tumors
Number of subjects: 1576
Study: 28746179

Group type: EXPERIMENTAL
Intervention: 200 mg of NBP soft capsules orally, 15 minutes before each meal, 3 times daily for 21 days
Number of subjects: 304

Group type: COMPARATOR
Intervention: 200 mg of placebo soft capsules orally, 15 minutes before each meal, 3 times daily for 21 days
Number of subjects: 304
Study: 26275714

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study: 23039152

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (usual therapy)
Number of subjects: 109
Study: 20347364

Group type: EXPERIMENTAL
Intervention: Fat mass ratio (FMR) evaluated by dual-energy X-ray absorptiometry (DXA)
Number of subjects: 221
Study: 18090507

Group type: EXPERIMENTAL
Intervention: Escitalopram (10‐20 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16827695

Group type: EXPERIMENTAL
Intervention: Additional dietary natural mineral water uptake
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 80
Study: 12810742

Group type: EXPERIMENTAL
Intervention: Handgun purchase for self
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Handgun purchase as a gift for a girl/boyfriend
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Handgun purchase for a girl/boyfriend 'because s/he needs it'
Number of subjects: 120

Group type: COMPARATOR
Intervention: Willingness to sell by region
Number of subjects: 120

Group type: COMPARATOR
Intervention: Illegal sale condition (need)
Number of subjects: 120
Study: 10925183

Group type: EXPERIMENTAL
Intervention: Apligraf(R) (Graftskin) applied over meshed split thickness autografts
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Apligraf(R) (Graftskin)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (meshed autograft covered with meshed allograft or not covered by a biologic dressing)
Number of subjects: 38
Study: 8645027

Group type: EXPERIMENTAL
Intervention: Tropisetron (T group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 98
Study: 1597847

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg three times daily for four weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 6089237

Group type: EXPERIMENTAL
Intervention: Conventional TENS - 80 Hz
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low frequency TENS - 2 Hz
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group - TENS without batteries
Number of subjects: 42
Study: 31774112

Group type: COMPARATOR
Intervention: BTLA rs1982809 SNP (AA genotype)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: TAAG haplotype (BTLA rs16859629, rs1982809, rs2171513, rs3112270)
Number of subjects: 1236
Study: 30414369

Group type: EXPERIMENTAL
Intervention: Ozone therapy (calcium channel blockers plus oxygen‐ozone treatment)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (calcium channel blockers only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27553267

Group type: EXPERIMENTAL
Intervention: Active stimulation (LH anodal/RH cathodal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active stimulation (RH anodal/LH cathodal)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study: 24556445

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion (PCV)
Number of subjects: 3940

Group type: COMPARATOR
Intervention: No cardioversion during admission
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: ECV with antiarrhythmic drugs (mostly amiodarone)
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: PCV with class Ic antiarrhythmic drugs
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: Chronic antiarrhythmic drugs, beta-blockers, or inhibitors of the renin-angiotensin system
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: Duration of hospital stay for ECV
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: Duration of hospital stay for PCV
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: CV-related complications
Number of subjects: 3940
Study: 22098133

Group type: EXPERIMENTAL
Intervention: Triple therapy plus L. gasseri-containing yogurt (112 g, twice daily for 4 weeks)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Triple therapy (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Triple therapy plus L. gasseri-containing yogurt
Number of subjects: 229

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 229
Study: 19287288

Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 86
Study: 17081222

Group type: EXPERIMENTAL
Intervention: Oral-appliance therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (age-matched males without sexual problems)
Number of subjects: 48
Study: 14985668

Group type: EXPERIMENTAL
Intervention: Oral phenytoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous phenytoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous fosphenytoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral phenytoin vs Intravenous phenytoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous fosphenytoin vs Intravenous phenytoin
Number of subjects: 0
Study: 11598356

Group type: EXPERIMENTAL
Intervention: Piezo-assisted ICSI
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional ICSI
Number of subjects: 204
Study: 10916570

Group type: EXPERIMENTAL
Intervention: PRISCA 3.0 software for twin pregnancy
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Ulm Index for fetal trisomy 21 risk calculation
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: AFP determination for fetal open NTD in twin pregnancy
Number of subjects: 889

Group type: COMPARATOR
Intervention: PRISCA 3.0 software for singleton pregnancy
Number of subjects: 889

Group type: COMPARATOR
Intervention: AFP determination for fetal open NTD in singleton pregnancy
Number of subjects: 889
Study: 8052154

Group type: EXPERIMENTAL
Intervention: D-fenfluramine 15 mg twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3132220

Group type: EXPERIMENTAL
Intervention: Radial immunodiffusion
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Hemoccult II with rehydration
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Hemoccult II without rehydration
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Immunological technique
Number of subjects: 1328
Study: 29172605

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Waiting-List Control (WLC)
Number of subjects: 62